The Gap Between Patent Data and Supply Chain Decisions Every procurement director at a hospital system, every formulary manager at […]

The Decision That Determines Your Revenue Ceiling Somewhere between completing a Phase II study and walking into an FDA pre-NDA

The Moment the Monopoly Ends On November 30, 2011, Lipitor lost its U.S. patent protection. Within 90 days, the price

The Problem With Waiting Every year, branded pharmaceutical companies watch billions in revenue walk out the door, and generic manufacturers

Drug companies don’t make drugs. They make time. Patents are the mechanism by which a pharmaceutical firm converts a decade

The $3.5 Billion Miscalculation In 2011, Warner Chilcott and Allergan settled a Paragraph IV lawsuit over the branded proton pump

The Five-Year Window Is Not Generous When a branded drug loses patent exclusivity, its manufacturer does not get to negotiate

How generic and 505(b)(2) developers mine expired and lapsed pharmaceutical patents for low-cost market entry The drug development world has

The Patent Cliff Is Real, and So Is the Industry’s Response Every pharmaceutical executive knows the feeling. A blockbuster drug